Home
About
Overview
Sharing Data
ORCID
Help
History (12)
Limb Perfusion Delivery of a rAAV1 Alpha-1 Antitrypsin Vector in Non-Human Primates Is Safe but Insufficient for Therapy.
Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling.
Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines.
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy. Reply.
Genetic modifiers of p53: opportunities for breast cancer therapies.
See All 12 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Genetic modifiers of p53: opportunities for breast cancer therapies.
Majhi PD, Sharma A, Jerry DJ. Genetic modifiers of p53: opportunities for breast cancer therapies. Oncotarget. 2023 03 24; 14:236-241.
View in:
PubMed
subject areas
Breast Neoplasms
Female
Genes, p53
Genetic Predisposition to Disease
Germ-Line Mutation
Humans
Li-Fraumeni Syndrome
Tumor Suppressor Protein p53
authors with profiles
D Joseph Jerry BS, MS, PhD